FORA Capital LLC Invests $412,000 in Certara, Inc. (NASDAQ:CERT)

FORA Capital LLC acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 17,100 shares of the company’s stock, valued at approximately $412,000.

Several other large investors also recently bought and sold shares of the business. Clearbridge Investments LLC grew its stake in Certara by 19.3% during the 1st quarter. Clearbridge Investments LLC now owns 3,877,794 shares of the company’s stock valued at $93,494,000 after acquiring an additional 626,394 shares in the last quarter. Public Sector Pension Investment Board purchased a new stake in Certara during the 1st quarter valued at about $4,482,000. Sei Investments Co. grew its stake in Certara by 72.1% during the 1st quarter. Sei Investments Co. now owns 180,704 shares of the company’s stock valued at $4,357,000 after acquiring an additional 75,728 shares in the last quarter. NewEdge Advisors LLC grew its stake in Certara by 384,525.0% during the 1st quarter. NewEdge Advisors LLC now owns 30,770 shares of the company’s stock valued at $742,000 after acquiring an additional 30,762 shares in the last quarter. Finally, Pearl River Capital LLC purchased a new stake in Certara during the 1st quarter valued at about $250,000. Hedge funds and other institutional investors own 67.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. TheStreet cut shares of Certara from a “c-” rating to a “d+” rating in a research note on Friday, June 16th. Bank of America dropped their price target on shares of Certara from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, August 15th. William Blair cut shares of Certara from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Credit Suisse Group dropped their price target on shares of Certara from $27.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, August 10th. Finally, Barclays dropped their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, August 11th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $21.13.

Certara Stock Performance

Shares of CERT stock opened at $15.17 on Thursday. The firm’s 50 day moving average price is $17.73 and its 200-day moving average price is $20.01. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.43 and a current ratio of 3.43. Certara, Inc. has a one year low of $10.60 and a one year high of $24.96. The firm has a market cap of $2.42 billion, a P/E ratio of 126.43, a P/E/G ratio of 1.03 and a beta of 1.46.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. The firm had revenue of $90.45 million for the quarter, compared to analyst estimates of $92.04 million. Certara had a net margin of 5.45% and a return on equity of 5.56%. As a group, equities research analysts predict that Certara, Inc. will post 0.34 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.